WebJan 15, 2007 · GUIDELINES AND RECOMMENDATIONS FOR DOSING CHEMOTHERAPEUTIC AGENTS WITH HEPATIC DYSFUNCTION. ADJUSTMENT … WebDec 20, 2024 · Patients undergoing chemotherapy for cancer using conventional cytotoxic agents, molecularly targeted agents, and immunotherapeutic agents, require careful assessment of liver function both prior to and during therapy. Potential interactions …
Cytarabine (Conventional): Dosage, Mechanism/Onset of Action, …
WebDose Modifications The dose modifications listed are for haematological, liver and renal function and drug specific toxicities only. Dose adjustments may be necessary for other toxicities as well. In principle all dose reductions due to adverse drug reactions should not be re-escalated in subsequent cycles without consultant approval. WebTo guide clinicians in selecting appropriate dose adjustments, information from available drug labels and from the published literature were combined to provide a practical set of recommendations for dose adjustments of … philip road staines
Annex III Summary of product characteristics, labelling …
WebApr 20, 2024 · CONSOLIDATION THERAPY: 12 mg/m2 given IV daily on days 1 and 2 (in combination with cytarabine given as a continuous 24-hour IV infusion on days 1 to 5). The first course is given approximately 6 weeks after the final induction course and the second is generally administered 4 weeks after the first. Comments: WebKintzel recommends for CrCl of 46–60 mL/min, give 85% of dose; for CrCl of 31–45 mL/min, give 75% of dose; and for CrCl of ,30 mL/min, give 70% of dose. Aronoff recommends giving 75% of the dose for a CrCl of .10–50 mL/min and 50% for those with a … WebThe ADDIKD guideline does not address dose adjustment for kidney dysfunction in stem cell mobilisation, bone marrow transplantation and cellular therapies. In these circumstances, the transplant team should be consulted if the patient has kidney dysfunction and is requiring one of the drugs referred to in ADDIKD as part of their treatment. philip road ipswich